JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes

By Georg Ostermann, K. Weber, A. Zernecke, A. Schröder, Christian Weber. Nature Immunology, 2002

716 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Nr4a1-Dependent Ly6Clow Monocytes Monitor Endothelial Cells and Orchestrate Their Disposal (2013, neutral): “LFA1 (aLb2 integrin) accepts several ligands, including ICAM1, ICAM2, ICAM3, and JAM-A (de Fougerolles et al., 1993; Marlin and Springer, 1987; Ostermann et al., 2002; Staunton et al., 1989).”
The blood-brain barrier in brain homeostasis and neurological diseases. (2009, neutral): “conditions, JAM-A is redistributed from intercellular junctions to the endothelial apical membrane where they bind the leukocyte integrin LFA-1 (αLβ2) [80,81], thus possibly contributing to leukocyte diapedesis and migration to the brain [82,83].”
Mechanisms of Leukocyte Transendothelial Migration (2011, background): “Although it normally engages in homophilic adhesion, during inflammation it can bind to CD11a/ CD18 on the leukocyte (15).”
The blood-brain barrier in Alzheimer's disease (2017, neutral): “However, JAMs also engage leukocyte integrins in a heterophilic manner, and may participate in leukocyte extravasation during in ﬂ ammatory responses (Del Maschio et al., 1999; Ostermann et al., 2002; Santoso et al., 2002; Muller, 2003).”
Reactive Oxygen Species in Inflammation and Tissue Injury (2014, neutral): “This heterophilic interaction regulated leukocyte–endothelial cell and leukocyte–platelet interactions (326, 329, 373).”